ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 41226789

Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.

Darman L and 4 others. Int J Mol Sci, 2025. Cited by 6 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1. Papers, record 41226789. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41226789

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.37, provisional
iCite
Revised in PubMed
2025-11-16
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Darman LLily
2Kaurich QQuinnhttps://orcid.org/0000-0002-4974-898X
3Hassan MSMd Sazzadhttps://orcid.org/0000-0001-6309-9616
4von Holzen UUrs
5Awasthi NNiranjan

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CholangiocarcinomaMajor topic
Bile Duct NeoplasmsMajor topic
Molecular Targeted TherapyMajor topic
Isocitrate DehydrogenaseMajor topic
Receptor, Fibroblast Growth Factor, Type 2Major topic
Humans
Antineoplastic Agents

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
23-817-16Indiana University School of MedicinePubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References131

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137,444,422Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies.Cancers (Basel)2023https://conductscience.org/library/papers/37444422PubMed
229,527,009Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.Br J Cancer2018https://conductscience.org/library/papers/29527009PubMed
328,317,403Intrahepatic cholangiocarcinoma: current management and emerging therapies.Expert Rev Gastroenterol Hepatol2017https://conductscience.org/library/papers/28317403PubMed
426,582,900AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.Sci Transl Med2015https://conductscience.org/library/papers/26582900PubMed
536,046,845Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy.Explor Target Antitumor Ther2022https://conductscience.org/library/papers/36046845PubMed
624,581,682Cholangiocarcinoma.Lancet2014https://conductscience.org/library/papers/24581682PubMed
725,989,801Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review.Cancer Res Treat2015https://conductscience.org/library/papers/25989801PubMed
833,686,772Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.Cancer Sci2021https://conductscience.org/library/papers/33686772PubMed
927,095,655Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Nat Rev Gastroenterol Hepatol2016https://conductscience.org/library/papers/27095655PubMed
1028,183,697Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).Cancer Discov2017https://conductscience.org/library/papers/28183697PubMed

1 to 10 of 131

See all 131 references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42,881,857
Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.
J Clin Med2026https://conductscience.org/library/papers/42881857PubMed
42,629,442Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation.Oncogene2026https://conductscience.org/library/papers/42629442PubMed
42,564,789Multifunctional LA and PTMC coating for biliary stents to combat cholangiocarcinoma proliferation in obstruction.iScience2026https://conductscience.org/library/papers/42564789PubMed
42,449,676Prognostic, Predictive, and Clinical Relevance of DNA Damage Repair Alterations in Biliary Tract Cancers.Cancers (Basel)2026https://conductscience.org/library/papers/42449676PubMed
42,362,876The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic Cholangiocarcinoma.Ann Surg Oncol2026https://conductscience.org/library/papers/42362876PubMed
42,196,390Recent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy.Int J Mol Sci2026https://conductscience.org/library/papers/42196390PubMed
41,976,167Synergistic Effects of Atractylodes-Derived Sesquiterpenes and Polyacetylene on Chemotherapeutic Sensitivity in Cholangiocarcinoma: Impact on Transporter Gene Expression.Molecules2026https://conductscience.org/library/papers/41976167PubMed

Genes13

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
FGFR22,263PubTator's text mininghttps://conductscience.org/library/genes/2263NCBI Gene
IDH13,417PubTator's text mininghttps://conductscience.org/library/genes/3417NCBI Gene
KDR3,791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
KRAS3,845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene
MDM24,193PubTator's text mininghttps://conductscience.org/library/genes/4193NCBI Gene
PDGFRB5,159PubTator's text mininghttps://conductscience.org/library/genes/5159NCBI Gene

1 to 10 of 13

See all 13 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41226789

GET https://conductscience.org/api/papers/v1/41226789/references?page=2

API referenceFor AI assistants